Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial - Concepedia

Concepedia

Publication | Open Access

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial

DOI Full Paper Access

50

Citations

20

References

2018

Year

Edward Fox, Clyde Markowitz, Angela Applebee, Xavier Montalbán, Jerry S. Wolinsky, Shibeshih Belachew, Damian Fiore, Jinglan Pei, Bruno Musch, Gavin Giovannoni

Multiple Sclerosis Journal

Abstract

Ocrelizumab reduces the risk of UE disability progression and may increase the possibility of improvement versus placebo in PPMS.

References

	Year	Citations

Page 1